Tridek-One

About

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

Évry,Ile-de-France,France
1 - 10

Highlights

Details

Last Funding Type: Series Unknown
Last Funding Money Raised: €16M
Industries: Biotechnology,Health Care,Life Science
Founded date: Jan 1, 2018
Number Of Employee: 1 - 10
Operating Status: Active

Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

€19M

Tridek-One has raised a total of €19M in funding over 2 rounds. Their latest funding was raised on Sep 15, 2022 from a Series Unknown round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 15, 2022	Series Unknown	€16M	5	Pureos Bioventures	—	Detail
Jun 4, 2019	Series Unknown	€3M	2	AdBio partners	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

5

Tridek-One is funded by 5 investors. Pureos Bioventures and AdBio partners are the most recent investors.

Investor Name	Lead Investor	Funding Round
Pureos Bioventures	Yes	Series Unknown
AdBio partners	—	Series Unknown
Advent Life Sciences	—	Series Unknown
Bioqube Ventures	—	Series Unknown
Bpifrance	—	Series Unknown